Avelas Biosciences

Avelas Biosciences is a clinical-stage biotechnology company and a pioneer in the field of intraoperative fluorescence cancer imaging. The company focuses on developing pegloprastide (also known as AVB-620), a novel drug-device combination product for cancer surgery. Pegloprastide aims to improve surgical outcomes by enabling real-time detection of cancer and has the potential to become part of the standard treatment for various types of cancer surgeries. At Avelas Biosciences, their mission is to advance a new standard of care in cancer surgery by providing tumor surgeons with real-time luminescence imaging, thereby improving surgical results and delivering better outcomes for patients.